SYGNIS completes X-Pol Biotech acquisition
SYGNIS Pharma AG announced that the merger with X-Pol Biotech S.L. (X-Pol) is completed. With the approval of the Annual General Meeting on October 17, 2012 SYGNIS acquired 100% of the shares of the Spanish X-Pol by way of a capital increase against contribution in kind.
Thus X-Pol becomes a 100% subsidiary of SYGNIS and SYGNIS’ share capital is increased from € 2,103,688 to € 9,349,724. After this transaction, the former shareholders of X-Pol hold 77.5% of SYGNIS shares. The previous shareholders of SYGNIS now own 22.5% of the new company. No shares were sold in the capital market.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.